Shows
OncLive® On AirASCO 2025 Plenary — MATTERHORN
Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.
In this episode, OncLive On Air® partnered with Two Onc Docs to bring a discussion of key data from the phase 3 MATTERHORN t...2025-07-0812 minOncLive® On AirASCO 2025 Plenary: SERENA-6In this episode, OncLive On Air® partnered with Two Onc Docs to bring discussion of data from the phase 3 SERENA-6 trial (NCT04964934), which were presented at the 2025 ASCO Annual Meeting. SERENA-6 evaluated switching to camizestrant plus a CDK4/6 inhibitor vs continuing with a standard-of-care aromatase inhibitor plus a CDK4/6 inhibitor in the frontline setting in patients with hormone receptor–positive, HER2-negative advanced breast cancer whose tumors harbor an emergent ESR1 mutation. Drs Armstrong and Tawagi highlighted key efficacy, safety, and patient-reported outcomes from the study. They also noted the clinical implications of these findings, including how they might be cur...2025-06-2412 min
OncLive® On Air42nd Annual Miami Breast Cancer Conference® Podcast: OncLive On Air CE, Powered by PER
Episode Description
In this podcast, expert Hope Rugo, MD, discusses her approach to treating patients with hormone receptor–positive/HER2-negative breast cancer from the early-stage to metastatic disease. Consideration of these complex clinical scenarios taken from tumor board discussions at the 42nd Annual Miami Breast Cancer Conference® highlight evolving strategies in breast cancer care and clinical decision-making.
Acknowledgment of Educational Grant Support
This activity is supported by educational grants from Exact Sciences Corporation; Lilly; Merck & Co, Inc; Novartis; PreludeDx; Puma Biotechnology, Inc; and Varian Medical Systems, Inc.
Today’s faculty is:
2025-06-1826 min
OncLive® On AirStudy Reveals Subgroups of Patients With RCC Who May Have Durable Responses to Immunotherapy: With David A. Braun, MD, PhDIn today’s episode, OncLive teamed up with CURE to present a discussion with David A. Braun, MD, PhD, about his research on determinants of response to immune checkpoint inhibition (ICI) in patients with renal cell carcinoma (RCC). Dr Braun is an assistant professor of medicine (medical oncology), the Louis Goodman and Alfred Gilman Yale Scholar, and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center in New Haven, Connecticut.
In this exclusive interview, Dr Braun discussed the rationale for investigating molecular factors that contribute to exceptional ICI responses among patients with RCC, as...2025-03-2815 min
OncLive® On AirNeoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MDIn this episode of Oncology Unplugged, a podcast series from OncLive and MedNews Week, podcast host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD, to talk about a pilot trial investigating neoadjuvant accelerated methotrexate, vinblastine,doxorubicin, and cisplatin (aMVAC) plus pembrolizumab (Keytruda) in patients with non-urothelial muscle-invasive bladder cancer, findings from which were presented at the 2025 Genitourinary Cancers Symposium. Dr Grivas is clinical director of the Genitourinary Cancers Program and a professor in the Clinical Research Division at Fred Hutchinson Cancer Center, as well...2025-02-2620 min
OncLive® On AirMedNews Week Advances Global Oncology Education and Combats Misinformation: With Chandler Park, MD; and Yan Leyfman, MDIn this episode of Oncology Unplugged, a podcast series from OncLive and MedNews Week, podcast host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, and Yan Leyfman, MD, a resident physician at Mount Sinai in New York, New York, discussed the origins and mission of MedNews Week, a global platform designed to combat health care misinformation and advance medical education. Conceived during the COVID-19 pandemic, MedNews Week was created in response to widespread misinformation and a need for accessible, evidence-based information. Over the past 2 and a half years, the platform has expanded to reach over 100...2025-01-1519 min
OncLive® On AirTrastuzumab Deruxtecan Advances HER2+ Gynecologic Cancer Care: With Susana M. Campos, MD, MPHOncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we had the pleasure of speaking with Susana M. Campos, MD, MPH, about the role of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in patients with HER2-positive gynecologic cancers. Dr Campos is the clinical director and the director of Educational Initiatives in the Division of Gynecologic Oncology at Dana-Farber Cancer Ins...2024-11-2107 min
OncLive® On AirBoard Review Resources 2024
Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.
In this episode, OncLive On Air® partnered with Two Onc Docs to bring you a curated list of resources to use as y...2024-09-3015 min
OncLive® On AirThomas and Lukas Highlight Updates in Brain Cancer from the 2024 ASCO Annual MeetingWelcome to OncLive On Air®! I’m your host today, Ashling Wahner.
OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we had the pleasure of speaking with Tarita Thomas, MD, PhD, MBA, and Rimas Lukas, MD, about abstracts presented during a brain cancer–focused clinical science symposium at the 2024 ASCO Annual Meeting. Dr Thomas is an assoc...2024-09-1915 min
OncLive® On AirFDA Approval Insights: Epcoritamab in Relapsed/Refractory Follicular LymphomaWelcome to OncLive On Air®! I’m your host today, Ashling Wahner.
OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, supported by AbbVie, we had the pleasure of speaking with Jennifer Crombie, MD, about the FDA approval of epcoritamab-bysp (Epkinly) for patients with relapsed/refractory follicular lymphoma. Dr Crombie is a physician at Dana-Farber Cancer In...2024-09-1609 min
OncLive® On AirHeme & Onc Fellow Board Review Tips 2024
Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.
In this episode, OncLive On Air® partnered with Two Onc Docs to bring you a review session for the oncology board exams. D...2024-09-0916 min
OncLive® On AirASCO 2024 Plenary: ADRIATIC Trial in Limited-Stage Small Cell Lung CancerOncLive On Air partners with Two Onc Docs to bring insights on the ADRIATIC trial, data from which were presented at the 2024 ASCO Annual Meeting.2024-07-0812 min
OncLive® On AirASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLCOncLive On Air partners with Two Onc Docs to bring insights on primary data from the LAURA trial, which were presented at the 2024 ASCO Annual Meeting.2024-06-1012 min
OncLive® On AirCleveland Clinic Faculty Speak to Shifting Standards in Hematologic MalignanciesWe had the pleasure of speaking with faculty from an OncLive® Institutional Perspectives in Cancer webinar on hematologic malignancies, hosted in partnership with Cleveland Clinic, to discuss current practice patterns and emerging therapies in chronic myeloid leukemia, chronic lymphocytic leukemia, myelofibrosis, and acute lymphoblastic leukemia.2022-02-1022 min
OncLive® On AirFDA Approval Insights: Sacituzumab Govitecan in Urothelial CancerDr. Tagawa discusses the FDA approval of sacituzumab govitecan in urothelial cancer, key efficacy and safety data from the pivotal TROPHY-U-01 trial, and expectations for the confirmatory TROPiCS-04 trial.2021-07-2209 minOncLive® On AirJabbour on Tailoring Treatment With TKIs in CML and Ph+ ALLDr. Jabbour discusses the optimal use of ponatinib in chronic myeloid leukemia and data from the 2021 ASCO Annual Meeting with the combination of blinatumomab and ponatinib in Ph-positive acute lymphoblastic leukemia.2021-07-1915 minOncLive® On AirMayer on the Optimization of SERDs in ER+ Breast CancerDr. Mayer discusses the mechanism of action of SERDs in ER-positive breast cancer, highlighted data from the AMEERA-1 trial with amcenestrant and palbociclib, and details future research efforts with SERDs.2021-07-1519 minOncLive® On AirWainberg Weighs In on Advances in HER2+ GI CancersIn our exclusive interview, Wainberg discussed factors that help steer treatment selection in HER2-positive gastrointestinal malignancies, advances on the horizon, and more!2021-07-1209 minOncLive® On AirCTCA Leaders Provide Post-Pandemic Predictions in OncologyDr. Rariy, Ms. Brown, and Ms. Greenman discuss how the COVID-19 pandemic has led to a significant delay in cancer diagnoses, impacted the training of oncologists, and revolutionized telehealth.2021-07-0826 minOncLive® On AirResearch Reflections: O'Malley Relays Key Updates in Ovarian and Endometrial CancersDr. O’Malley discusses key findings from 6 trials that were presented at the virtual 2021 SGO Annual Meeting on Women’s Cancer.2021-07-0515 minOncLive® On AirSherman Spotlights Advances With RET Inhibitors in Medullary Thyroid CancerDr. Sherman discusses the incidence of RET fusions in medullary thyroid cancer and the current clinical landscape of RET inhibitors in the field.2021-07-0116 minOncLive® On AirLee-Kim on Fostering a Fulfilling Fellowship in OncologyDr. Lee-Kim discusses her path into treating pediatric patients with cancer, key lessons that can be learned during fellowship, and tips on managing finances and burnout during a pediatric oncology fellowship program.2021-06-2823 minOncLive® On AirHalmos Highlights Effort Exploring COVID-19 Vaccines in Patients With CancerDr. Halmos discusses the data from a study examining seroconversion rates following COVID-19 vaccination among patients with cancer and underscores the need for novel vaccination or passive immunization strategies for immunosuppressed cohorts.2021-06-2414 minOncLive® On AirMatsen Reflects on Changes to Breast Cancer Surgery During COVID-19Dr. Masten reflects on the main challenges that arose during the COVID-19 lockdown with regard to surgery in patients with breast cancer, the steps that were taken as the lockdown started to lift, and the changes that have been made with regard to managing patients around the time of surgery and in the operating room.2021-06-2121 min
OncLive® On AirGeorge Gives Take on Optimal Sequencing, Strategies in Pancreatic Cancer PipelineDr. George discusses treatment considerations in the first-line setting of metastatic pancreatic cancer, signs that may indicate disease progression and the need for second-line therapy, and investigational agents in the pipeline.2021-06-1725 minOncLive® On AirPant Projects an Expanding Role for Targeted Therapy in Pancreatic CancerDr. Pant discusses the current role for germline and somatic testing in pancreatic cancer, examines the research landscape with PARP inhibitors, KRAS inhibitors, and other targeted agents, and shares his hope for the future of drug development in the field.2021-06-1415 minOncLive® On AirPatel Previews Collaborative Research Program With SD-101 in Uveal MelanomaDr. Patel discusses the significance of the new collaboration between The University of Texas MD Anderson Cancer Center and TriSalus™ Life Sciences and the resulting research evaluating the administration of an investigational toll-like receptor 9 (TLR9) agonist in combination with immunotherapy across a range of liver and pancreatic solid tumors.2021-06-1012 minOncLive® On AirFDA Approval Insights: Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma2021-06-0711 minOncLive® On AirFDA Approval Insights: Tivozanib in Relapsed/Refractory Advanced RCCDr. Rini discusses unique elements of the TIVO-3 trial, the significance of the FDA approval of tivozanib in advanced RCC, and potential next steps for research with the TKI in the paradigm.2021-06-0310 minOncLive® On AirLandgren Breaks Down the Benefit of Novel Quadruplet in Newly Diagnosed MyelomaDr. Landgren discusses the potential of a quadruplet regimen comprised of carfilzomib, lenalidomide, dexamethasone, and daratumumab in the treatment of patients with newly diagnosed multiple myeloma.2021-05-3116 minOncLive® On AirBaumann Characterizes the Current Treatment Landscape of Merkel Cell CarcinomaDr. Baumann sheds light on the incidence, prognosis, and treatment of patients with Merkel cell carcinoma, ongoing clinical research, and strategies to raise awareness for this rare disease.2021-05-2719 minOncLive® On AirKaklamani Speaks to a Shifting HER2+ Breast Cancer ParadigmIn our exclusive interview, Kaklamani discussed current treatment sequencing approaches in HER2-positive breast cancer and the benefits and challenges of moving effective treatments in earlier lines of therapy.2021-05-2412 minOncLive® On AirUCSD Faculty Contextualize Cases of Cutaneous Squamous Cell CarcinomaIn our exclusive interview, Drs Park, Daniels, Sanghvi, and Kolb, discussed two high-risk non-melanoma skin cancer cases and highlighted patient and tumor risk factors to consider in the clinical setting.2021-05-2032 minOncLive® On AirGrivas and Wright Weigh In on the Benefits of Multidisciplinary Care in Bladder CancerIn our exclusive interview, Drs Grivas and Wright discussed the goals of the Seattle Cancer Care Alliance Bladder Cancer Multidisciplinary Clinic, data that support the use of a multidisciplinary approach in bladder cancer, and the lingering effects of the COVID-19 pandemic on collaboration across health care specialties.2021-05-1726 min
OncLive® On AirO'Dea Offers Insight Into the Integration of Trastuzumab Deruxtecan in HER2+ Breast CancerIn our exclusive interview, O’Dea discussed the efficacy and safety of trastuzumab deruxtecan in patients with HER2-positive breast cancer, treatment sequencing recommendations, and future research directions for antibody-drug conjugates in the field.2021-05-1316 minOncLive® On AirFederico Outlines Needs, Nuances, and Necessities in Neuroblastoma TreatmentIn our exclusive interview, Dr. Federico discussed the diagnosis and presentation of neuroblastoma, the role of multidisciplinary care, and novel therapies that could significantly affect the treatment paradigm for this malignancy.2021-05-1022 minOncLive® On AirFDA Approval Insights: Cemiplimab in Advanced PD-L1–High NSCLC and Advanced Basal Cell CarcinomaDr. Sezar and Dr. Stratigos discuss the FDA approvals of cemiplimab-rwlc in advanced non–small cell lung cancer and advanced basal cell carcinoma.2021-05-0613 minOncLive® On AirFDA Approval Insights: Liso-Cel in Refractory Large B-Cell LymphomaDr. Abramson discusses the significance of the FDA approval of liso-cel in refractory large B-cell lymphoma and provided insight into the efficacy and safety profiles of the CAR T-cell therapy as reported in the TRANSCEND NHL 001 trial.2021-05-0310 minOncLive® On AirRiedel and Van Tine Spotlight Sarcoma Advances and Preview Ongoing StudiesIn our exclusive interview, Riedel and Van Tine discussed the multidisciplinary management of patients with sarcoma, the clinical impact of the FDA approval of ripretinib in the gastrointestinal stromal tumor paradigm, and other exciting advances in sarcoma.2021-04-2924 minOncLive® On AirFDA Approval Insights: TheraSphere Y-90 Glass Microspheres in HCCRiad Salem, MD, discusses the unique elements of the radioembolization technology, the data that supported the regulatory approval, and the anticipated future for TheraSphere in HCC.2021-04-2614 minOncLive® On AirPagel Unpacks the Utility of PI3K Inhibitors in Lymphoid MalignanciesDr. Pagel discusses the advances that have been made with PI3K inhibitors in lymphoid malignancies, the impact of the FDA approval of umbralisib on the treatment paradigm in follicular lymphoma and marginal zone lymphoma, and ongoing research poised to expand the armamentarium.2021-04-2219 minOncLive® On AirSaba Spotlights the Nuances of Treating Nasopharygeal CancerDr. Saba shared the ins and outs of nasopharyngeal carcinoma, ongoing clinical trials, and the complexities of managing the rare disease.2021-04-1917 min
OncLive® On AirResearch Reflections: Sonpavde on Urothelial Cancer Updates From the 2021 GU Cancers SymposiumDr. Sonpavde discusses key data presented during the 2021 Genitourinary Cancers Symposium in urothelial carcinoma and anticipated research directions with immunotherapy, chemotherapy, and antibody-drug conjugates.2021-04-1517 minOncLive® On AirFDA Approval Insights: Umbralisib in Marginal Zone Lymphoma and Follicular LymphomaIn our exclusive interview, Fowler discussed the data that served as the basis for the accelerated approval of umbralisib in marginal zone lymphoma and follicular lymphoma, explained the implications of the regulatory decision on clinical practice, and detailed potential next steps for the PI3Kδ and CK1ε inhibitor.2021-04-1209 minOncLive® On AirFDA Approval Insights: Trilaciclib in Extensive-Stage Small Cell Lung CancerIn our exclusive interview, Weiss discussed the significance of the FDA approval of trilaciclib in extensive-stage small cell lung cancer and key efficacy and safety data that have been reported with the CDK4/6 inhibitor.2021-04-0818 min
OncLive® On AirChoueiri and Motzer Chat on CheckMate-9ER and Other RCC ResearchIn our exclusive interview, Dr. Choueiri and Dr. Motzer discuss the clinical implications of the phase 3 CheckMate-9ER trial in advanced renal cell carcinoma and how to best use the combination in practice.2021-04-0520 minOncLive® On AirThe Marshalls Open a Candid Conversation About CancerThe Marshalls go beyond the pages of their new memoir, Off Our Chests: A Candid Tour Through the World of Cancer, to discuss how Liza's diagnosis of triple-negative breast cancer changed their lives and the key messages they hope readers will take from their book.2021-04-0138 min
Cancer HorizonsOff Our Chests: An Oncologist Turned Caregiver and His Wife Share Their Cancer Journey From All AnglesOne pair – Dr. John Marshall and his wife, Liza – have been surrounded by cancer since John became an oncologist early on in their marriage. The duo never imagined the disease would dramatically change their world when Liza was diagnosed with stage 3 triple-negative breast cancer.
John was without a doubt impacted by the unexpected diagnosis as he had to learn how to juggle between playing a caregiver and being a doctor at the same time, while Liza, the matriarch of the family who was always in charge of her own health, leaned on her husband for support and medical advice.
In the bo...2021-04-0139 minOncLive® On AirHu Highlights Recent Advances and Approvals in RET-Altered Thyroid CancerDr. Hu discusses the importance of testing for RET alterations in thyroid cancer, the FDA approvals of selpercatinib and pralsetinib, and the changing dynamics between medical oncologists and endocrinologists.2021-03-2915 minOncLive® On AirColeman and Brown Review Advancing Applications for PARP Inhibition in Ovarian CancerDr. Coleman and Dr. Brown discuss how understandings of BRCA and patient eligibility for PARP inhibitors have evolved in ovarian cancer, the effects of frontline maintenance trials on treatment recommendations, the clinical significance of the findings from the ARIEL4 trial, and where PARP inhibition is headed in the field.2021-03-2519 minOncLive® On AirBorgen Breaks Down the Domino Effect of Expanded Education and Banished Stigmas in Male Breast CancerPatrick I. Borgen, MD, discusses male breast cancer in further detail, how he approaches treatment in his male patients with the disease, and what can be done to remove the stigma that men often feel with a breast cancer diagnosis.2021-03-2216 minOncLive® On AirMonk and Herzog Hammer Out PARP Nuances in Ovarian CancerIn our exclusive interview, Monk and Herzog discussed the importance of molecular testing in ovarian cancer and the utility of PARP inhibitor maintenance and treatment.2021-03-1821 min
OncLive® On AirSpira Spotlights Sotorasib and Targeting KRAS Mutations in NSCLCIn our exclusive interview, Dr. Spira discusses the historical challenges of targeting KRAS, key findings from the phase 2 CodeBreaK 100 trial with sotorasib in KRAS G12C-mutant solid tumors, and the next steps of development for KRAS inhibitors in oncology.2021-03-1612 min
Health Professional Radio - PodcastInformation for Men with Prostate CancerReturning guest, Dr. Neal Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center discusses the importance of patient-centric treatment decision-making and the publication of an easy-to-understand summary of important clinical trial data in "Future Oncology", a leading medical journal (Online Feb 2021).
Neal D. Shore, MD, FACS, is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 350 clinical trials, focusing mainly on genitourinary oncology, and serves on the executive boards of the Society of Urologic Oncology and the Bladder...2021-03-1410 minOncLive® On AirLevy Lauds Biomarker-Driven Data in Lung CancerDr. Levy discusses key research efforts with targeted therapies for patients with lung cancer who harbor NTRK, KRAS, and HER2 aberrations.2021-03-1119 minOncLive® On AirFDA Approval Insights: Trastuzumab Deruxtecan in HER2+ Metastatic Gastric/GEJ CancerIn our exclusive interview, Dr. Shitara discussed the significance of the FDA approval of trastuzumab deruxtecan in HER2-positive gastric and GEJ adenocarcinoma and key efficacy and safety data that have been reported with the agent.2021-03-0810 minOncLive® On AirHeymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLChe incidence of EGFR exon 20 insertions in lung cancer, diagnostic challenges of identifying EGFR exon 20 insertions, and data from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer with mobocertinib and amivantamab in this patient subset.2021-03-0413 minOncLive® On AirFDA Approval Insights: Tepotinib in METex14-Altered Metastatic NSCLCIn our exclusive interview, Paul K. Paik, MD, provides perspective on the FDA approval of tepotinib in MET exon 14-altered metastatic NSCLC.2021-03-0115 minOncLive® On AirGrothey Spotlights the Growing HER2+ Paradigm in GI CancersIn our exclusive interview, Dr. Grothey discusses the excitement surrounding HER2-directed therapies in gastrointestinal malignancies, the approval of trastuzumab deruxtecan in HER2-positive metastatic gastric/gastroesophageal junction cancer, and the investigational agents patritumab deruxtecan and zanidatamab that are poised to further advance the paradigm.2021-02-2612 minOncLive® On AirNichols on Navigating the Nuances of von Hippel-Lindau DiseaseIn our exclusive interview, Dr. Nichols discussed VHL in great detail, how she currently approaches treatment with these patients, and the importance of routine surveillance in this population.2021-02-2219 minOncLive® On AirRodriguez Relays Insight Into the Integration of Immunotherapy in Lung CancerIn our exclusive interview, Rodriguez discussed historic treatments in lung cancer that preceded the integration of immunotherapy, shared current treatment selection and sequencing strategies, and forecasted the future of immunotherapy in the field.2021-02-1832 minOncLive® On AirSchilsky and Gralow Share Advice for ASCO Leadership and Therapeutic Equity in CancerDr. Schilsky highlights key milestones in his career with ASCO, Dr. Gralow speaks to the short- and long-term goals she plans to accomplish in her new role at ASCO, and both speak to their thoughts on the future of cancer care.2021-02-1527 minOncLive® On AirKlempner Keys in on the Pan-Tumor Potential of Seribantumab in NGR1+ Solid TumorsDr. Klempner provides insight into unmet needs in NRG1 fusion–positive solid tumors, the novelty of seribantumab, and the potential clinical implications of the ongoing CRESTONE study.2021-02-1119 minOncLive® On AirMarvels in Medicine: Dr. Slamon on a Career of Drug Development in OncologyDennis J. Slamon, MD, PhD, discusses how his passion for medicine stemmed from a high school biology class, the struggle to develop trastuzumab as a viable drug in HER2-positive breast cancer, and the movie about his research that he didn’t want to see made.2021-02-0827 minOncLive® On AirMesa and Gerds Talk Management Strategies and Emerging Agents in MyelofibrosisDr. Mesa and Dr. Gerds provided insight into the current utility of JAK inhibitors in myelofibrosis, unmet needs, and novel agents and combination strategies in the pipeline.2021-02-0424 min
OncLive® On AirSanborn and Gaffar Share Clinical and Economic Treatment Insights in NSCLC2021-02-0126 minOncLive® On AirSanborn and Gaffar Share Clinical and Economic Treatment Insights in NSCLCIn our exclusive interview, Dr. Sanborn and Dr. Gaffar share insight into the clincal and economic considerations for treatment in advanced NSCLC.2021-02-0126 minOncLive® On AirMarkman Talks Vilified Vaccines, Taboos, and Treatment for Cervical CancerDr. Markman discusses the clinical milestone of the HPV vaccine as a means to prevent cervical cancer, the debate on HPV-negative disease, and what efforts can be done on a global scale to reduce the incidence and mortality of cervical cancer.2021-01-2830 minOncLive® On AirFDA Approval Insights: Nivolumab/Cabozantinib in Advanced RCCIn our exclusive interview, Toni K. Choueiri, MD, provides additional perspective on the FDA approval of nivolumab and cabozantinib in advanced RCC.2021-01-2514 minOncLive® On AirForecasting Future Advances Across OncologyIn our exclusive interviews, each expert discussed their expectations for research and drug development in oncology in the new year.2021-01-2133 min
OncLive® On AirPursuing New Paradigms in Prostate CancerIn today’s episode, we had the pleasure of speaking with the faculty of a recent Institutional Perspectives in Cancer webinar on prostate cancer hosted by Yale Cancer Center.2021-01-1524 minOncLive® On AirPowles and Rini Put ctDNA Into Perspective in Urothelial CancerIn our exclusive interview, Dr. Powles and Dr. Rini provide insight into an analysis of the phase 3 IMvigor010 study and its implications for circulating tumor DNA as a biomarker in urothelial cancer and beyond.2021-01-1121 minOncLive® On AirBraunstein and Richter Talk Transplant and Therapy Options in Newly Diagnosed MyelomaIn our exclusive interview, Dr. Braunstein and Dr. Richter discuss navigating treatment selection for patients with newly diagnosed multiple myeloma and the evolving role of minimal residual disease.2021-01-0738 minOncLive® On AirSpotlighting Management Strategies Across Sarcoma SubtypesIn today’s episode, faculty of a recent Institutional Perspectives in Cancer webinar on sarcoma, hosted by Sylvester Comprehensive Cancer Center, share updates in the management of gastrointestinal stromal tumor, epithelioid and synovial sarcoma, and tenosynovial giant cell tumor.2021-01-0419 minOncLive® On AirLindau on Leading Successful Surgical FellowshipsIn our exclusive interview, Dr. Lindau discusses his journey into the head and neck surgery space, tips for a successful fellowship, and the importance of creating a family-like environment within the fellowship program he directs.2020-12-3121 minOncLive® On AirGaining Insight Into the Management of Gastrointestinal MalignanciesFaculty from a recent Institutional Perspectives in Cancer webinar on gastrointestinal cancer hosted by the University of Kentucky discuss the current paradigms in hepatocellular carcinoma, colorectal cancer, and pancreatic cancer.2020-12-2824 minOncLive® On AirDruker Details a Career of Determination, Patient Impact, and Family SuccessIn our exclusive interview, Dr. Druker discusses his journey into the field of oncology, the research that led to the initial approval of imatinib, why awards don’t impact his view on cancer care, and how becoming a family man has made him a better physician and scientist.2020-12-2426 minOncLive® On AirMultimodality Therapy Makes Waves in Bladder CancerFaculty from a recent Institutional Perspectives in Cancer webinar on bladder cancer hosted by Cleveland Clinic share updates in the management of metastatic urothelial carcinoma, as well as robotic cystectomy and bladder preservation approaches in muscle-invasive bladder cancer.2020-12-2118 minOncLive® On AirBorghaei and Gunuganti Break Down the Elements of Treatment Selection in NSCLCIn our exclusive interview, Borghaei and Gunuganti discussed patient selection for frontline immunotherapy, combination immunotherapy, and chemoimmunotherapy in NSCLC, the importance of PD-L1 expression, and emerging agents that are coming down the pike2020-12-1730 minOncLive® On AirLearning to Tailor Targeted and Immune Therapy in Lung CancerIn today’s episode, we had the pleasure of speaking with the faculty of the MedStar Georgetown University Hospital-sponsored Institutional Perspectives in Cancer webinar on lung cancer.
Faculty of the MedStar Georgetown University Hospital-hosted Institutional Perspectives in Cancer webinar on lung cancer spotlight key advances made with targeted therapies in lung cancer, the ways in which immunotherapy has complicated treatment decisions, and more!2020-12-1524 minOncLive® On AirBardia Brings to Light Complex Breast Cancer CasesIn our exclusive interview, Aditya Bardia, MD, MPH, sheds light on the considerations that should be made leading up to treatment selection in common clinical scenarios in breast cancer.2020-12-1016 min
OncLive® On AirRobert Recaps a Career of Clinical Research in MelanomaIn our exclusive interview, Caroline Robert, MD, PhD, discusses her groundbreaking work on clinical trials evaluating anti–CTLA-4 and anti–PD-1 antibodies in advanced melanoma, her experiences as a researcher in France and the United States, her love of traveling, and next steps for the field.2020-12-0732 minOncLive® On AirHuntsman Homes in on the Integration of Precision Medicine in OncologyIn our exclusive interview, Dr. Huntsman discusses the elements of precision medicine that have contributed to its growth in the field of oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.2020-12-0324 minOncLive® On AirMarvels in Medicine: Dr. Karlan on Creating Continuous Quality Improvement in Gynecologic OncologyIn our exclusive interview, Dr. Karlan discusses pivotal moments in her career as a gynecologic oncologist, the challenges of forging a name for herself, and future directions for the field.2020-11-3033 minOncLive® On AirLoaiza-Bonilla on Applications, Actionability, and Affordability of AI in OncologyIn our exclusive interview, Dr. Loaiza-Bonilla explains how AI can be used to optimize patient care, provides insight into the research that has been done to develop potential applications for AI in oncology, and sheds light on some of the barriers that have to be overcome in order to effectively implement AI in oncology.2020-11-2615 minOncLive® On AirOxnard on Opening the Door for Precision Medicine in Lung CancerIn our exclusive interview, Dr. Oxnard explained how precision medicine has affected the treatment landscape of lung cancer, discussed the current capabilities of liquid biopsy, and forecasted the future of precision oncology in the field.2020-11-2322 minOncLive® On AirMesa and Ulmer Measure Methods for JAK Inhibitor Optimization in MyelofibrosisIn our exclusive interview, Dr. Mesa and Dr. Ulmer discuss the current roles of ruxolitinib and fedratinib in myelofibrosis, current guidance for JAK inhibitor dosing, the utility of re-exposure to JAK inhibitors, and clinical trial options.2020-11-1932 minOncLive® On AirRaez Raises Concerns Over Delayed Cancer Care in the COVID-19 EraIn our exclusive interview, Raez discussed the reasons for these declines in routine screening and referrals, anticipated consequences, and some of the ways in which the health care community can combat these newfound challenges.2020-11-1611 minOncLive® On AirSaba Speaks to Tipifarnib and Targeting HRAS in Head and Neck CancerIn our exclusive interview, Nabil F. Saba, MD, FACP, sheds light on the implications of targeting HRAS in head and neck squamous cell carcinoma, details the data that has been reported to date with tipifarnib, and shares his expectations for the ongoing KO-TIP-007 trial.2020-11-1214 minOncLive® On AirAggarwal and Gandara on Incorporating Liquid Biopsies Into the Lung Cancer ArmamentariumIn our exclusive interview, Dr. Aggarwal and Dr. Gandara discuss the evolution of liquid biopsy in lung cancer, explain the clinical implications of recent liquid biopsy approvals, and forecast the future of liquid biopsy in the field.2020-11-0936 minOncLive® On AirTripathy Talks Genomics, Targeted Treatments, and Smart Trial Designs in Breast CancerIn our exclusive interview, Debu Tripathy, MD, considers the biological and long-term outcome variability of HR-positive, HER2-negative breast cancer and details the research that is being done to develop personalized treatment approaches.2020-11-0631 minOncLive® On AirLyman on Bringing Biosimilars From Bench to Bedside in OncologyIn our exclusive interview, Gary H. Lyman, MD, MPH, discusses the current state of biosimilars in oncology, the pathways that have been established to ensure the safe delivery of these agents to patients, and the potential effects they could have on alleviating some of the current constraints within the health care system.2020-11-0225 minOncLive® On AirRaez on the Rise of Liquid Biopsy in Lung CancerIn our exclusive interview, Dr. Raez provides insight into the advantages and disadvantages of liquid biopsy relative to tissue biopsy and forecasts the utility of liquid biopsy within the field of lung cancer as more of these assays become available.2020-10-2920 minOncLive® On AirFDA Approval Insights: Selinexor in Relapsed/Refractory DLBCLIn our exclusive interview, Brian T. Hill, MD, PhD, provides perspective on the FDA approval of selinexor in DLBCL.2020-10-2608 minOncLive® On AirFDA Approval Insights: Daratumumab/Carfilzomib/Dexamethasone in MyelomaToday, we had the pleasure of speaking with Saad Z. Usmani, MD, FACP, of Atrium Health, to discuss the FDA approval of daratumumab in combination with carfilzomib and dexamethasone for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.2020-10-2214 minOncLive® On AirGandara Evaluates Opportunities for Virtual Education, Expansion, and Engagement Amid COVID-19In our exclusive interview, David R. Gandara, MD highlights the benefits and challenges of delivering patient care virtually and its reception among patients, discusses the sustainability of virtual CME platforms and forecasts what the “new normal” of oncology education may look like as a result of the pandemic.2020-10-2022 minOncLive® On AirGarcia-Manero Previews Potential New Therapeutic Standards in TP53-Mutated MDS/AMLIn our exclusive interview, Guillermo Garcia-Manero, MD, discusses the prevalence of TP53 mutations in myelodysplastic syndromes and acute myeloid leukemia, the prognosis these mutations confer, and the development of eprenetapopt and magrolimab in this patient population.2020-10-1512 min
Relentless Health ValueEP296: Oncology FAQs About Telehealth, Standardizing Care, and Drug Prices, With Vincent Rajkumar, MD, of Mayo Clinic, RochesterMy guest in this health care podcast is Vincent Rajkumar, MD. Dr. Rajkumar is a professor of medicine at Mayo Clinic, Rochester. He’s also a practicing hematologist at the Mayo Clinic with a focus on multiple myeloma. Dr. Rajkumar does research and conducts clinical trials. He’s a well-known thought leader in questions about the cost of drugs in this country versus other countries. So, let me tell you what happened with this episode: I mentioned to a few people I would be speaking with Dr. Rajkumar, and every single person I mentioned it to sent me q...2020-10-1533 min
inspirED Interviews | Oncology, Cancer, & the World TodayLeaders in Med-Ed | Delivering Despite ChallengeHow does a medical education company transition during COVID-19? Listen in as we discuss logistics and innovation with top players in the industry – Teri Valls, from The Medical Educator Consortium, Kathy Clarke, from SageRock Advisors, Rita Piotti, from OncLive, and Ted Singer, from PeerView Institute for Medical Education.2020-08-111h 15Cancer HorizonsPatient-Doctor Duo: The Basics of Myeloproliferative NeoplasmsMyeloproliferative neoplasms, or MPNs, are a type of blood cancer that is often not heard about, which is why it is important for patients to speak with their doctors to learn more.
MPNS – essential thrombocythemia, myelofibrosis and polycythemia vera – begin with an abnormal change, or mutation, in a stem cell in the bone marrow, which leads to an overproduction of any combination of white cells, red cells and platelets.
In this special edition of the “CURE Talks Cancer” podcast, we teamed up with our sister publication “OncLive on Air” to speak with a patient-doctor duo on the disease. Learn more from Dr. Ruben...2020-04-1327 min